Cushing's Syndrome clinical trials at UC Health

• A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

  open to eligible people ages 18-80

  This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension

  at UCLA

Last updated: January 20, 2021